Ultragenyx Reports Inducement Grant Under Nasdaq Listing


NOVATO, Calif., Oct. 04, 2022 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical firm targeted on the event and commercialization of novel therapies for uncommon and ultra-rare ailments, at this time reported the grant of non-qualified inventory choices to buy an combination of 13,000 shares of widespread inventory of the corporate and 6,500 restricted inventory models of the corporate’s widespread inventory to 1 newly employed non-executive officer of the corporate. The awards had been authorised by the compensation committee of the corporate’s board of administrators and granted below the Ultragenyx Employment Inducement Plan, with a grant date of October 1, 2022, as an inducement materials to the brand new staff getting into into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted inventory models vest over 4 years, with 25% of the underlying shares vesting on every anniversary of the grant date, topic to the worker being constantly employed by the corporate as of such vesting dates. The inventory choices vest over 4 years, with 25% of the shares underlying the choice vesting on the primary anniversary of the grant date and the rest vesting with respect to 1/forty eighth of the shares underlying the choices on every month-to-month anniversary thereafter, topic to the worker being constantly employed by the corporate as of such vesting dates. The inventory choices have a ten-year time period and an train value of $41.41 per share, equal to the per share closing value of Ultragenyx’s widespread inventory on September 30, 2022.

About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical firm dedicated to bringing novel merchandise to sufferers for the therapy of great uncommon and ultra-rare genetic ailments. The firm has constructed a various portfolio of authorised therapies and product candidates geared toward addressing ailments with excessive unmet medical want and clear biology for therapy, for which there are sometimes no authorised therapies treating the underlying illness.

See also  Threat of third wave of Covid-19 poses risk to asset quality, especially the restructured loan book: ICRA

The firm is led by a administration crew skilled within the growth and commercialization of uncommon illness therapeutics. Ultragenyx’s technique is based upon time- and cost-efficient drug growth, with the purpose of delivering protected and efficient therapies to sufferers with the utmost urgency.

For extra info on Ultragenyx, please go to the corporate’s web site at: www.ultragenyx.com.

Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370

Source link


Please enter your comment!
Please enter your name here